Last reviewed · How we verify
GW406381
GW406381 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.
GW406381 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses. Used for Rheumatoid arthritis, Neuropathic pain.
At a glance
| Generic name | GW406381 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | P2X7 receptor antagonist |
| Target | P2X7 |
| Modality | Small molecule |
| Therapeutic area | Immunology / Neurology |
| Phase | Phase 3 |
Mechanism of action
P2X7 receptor antagonism reduces ATP-mediated activation of immune cells, particularly macrophages and microglia, thereby suppressing pro-inflammatory cytokine release and neuroinflammation. This mechanism is thought to be beneficial in conditions characterized by excessive inflammation and immune activation, particularly in the central nervous system.
Approved indications
- Rheumatoid arthritis
- Neuropathic pain
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment (PHASE1)
- COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis (PHASE3)
- Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee (PHASE3)
- Dental Pain (Following Third Molar Tooth Extraction) Study (PHASE3)
- GW406381 In Patients With Peripheral Nerve Injury (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW406381 CI brief — competitive landscape report
- GW406381 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI